Albumin companies

  • Report ID: 5035
  • Published Date: Aug 31, 2026
  • Report Format: PDF, PPT

Key Albumin Market Players:

    The worldwide market is vigorously gaining increased exposure with the presence of leading organizations, including Takeda, Grifols, and CSL Behring, collectively controlling the market with a combined share. These players have readily implemented strategies, such as biopharmaceutical partnerships and collaboration, research and development activities for recombinant albumin, plasma self-sufficiency, and market penetration. For instance, Seqirus and Baxter successfully partnered with each other to supply albumin for mRNA vaccine stabilizers. Likewise, LFB Group and Takeda initiated an investment for yeast-based alternatives to albumin, thereby creating a positive influence on the overall market.

    Here is a list of key players operating in the market:

    • CSL Behring (U.S.)
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Grifols (Spain)
    • Takeda Pharmaceuticals (U.S.)
    • Octapharma (Switzerland)
    • Baxter International (U.S.)
    • Kedrion Biopharma (Italy)
    • Biotest (Germany)
    • LFB Group (France)
    • Sanquin (Netherlands)
    • Bio Products Laboratory (UK)
    • SK Plasma (South Korea)
    • Biological E. Ltd. (India)
    • Serum Institute of India
    • Protheragen (Malaysia)
    • Seqirus (Australia)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of the albumin was over USD 8.4 billion.

The global albumin market size was USD 8.4 billion in 2026 and is likely to reach USD 17.8 billion by the end of 2036, expanding at a CAGR of 7.8% over the forecast period, i.e., 2027-2036.

The major players in the market are Baxter International, Kedrion Biopharma, Biotest, LFB Group, and others.

In terms of the source segment, the plasma-derived segment is anticipated to garner the largest market share of 58% by 2036 and display lucrative growth opportunities during 2026-2037.

The market in North America is projected to hold the largest market share of 37% by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos